second line regimen (1 factor) and more intensive treatments for the bad prognosis group (2 factors). High-dose therapy with autologous stem cell transplanKeywords: Hodgkin's disease; relapse; high-dose tation (ASCT) has been widely proposed for patients therapy; autologous bone marrow transplantation with relapsed Hodgkin's disease (HD). From 1982 to 1993, we selected (from the French registry for bone marrow transplantation) 280 patients, who underwent ASCT for relapsed HD after initial treatment including
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vival. Good prognostic factors for survival were: chemoDespite all these studies, it remains difficult to know sensitivity of relapse (P Ͻ 0.001) and first relapse vs whether all patients with relapsing HD will benefit signififurther relapse (P Ͻ 0.05). For 214 patients in first cantly from such intensive approaches and most reports in relapse, other significant factors for survival were: endthis context have included heterogeneous groups of of-treatment to relapse interval Ͻ12 months (P Ͻ 0.05) patients, including those with refractory disease and muland nodal vs extranodal relapse (P Ͻ 0.001). These two tiple relapses. [12] [13] [14] On the other hand, the high HD cure rate prognostic factors were used to validate a prognostic is associated with an increase of mortality not related to model with three significantly different subgroups: 0 (n disease progression. 15 For all these reasons, we decided to = 59), 1 (n = 125), or 2 factors (n = 30) with 4-year analyze HD patients reported to the Société Française de survival, respectively, at 93, 59 and 43% (P Ͻ 0.001).
Greffe de Moëlle. Among all the patients autografted from Salvage therapy can be tailored in patients with relaps-1982 to 1993, we selected 280 patients who relapsed after ing HD: conventional treatment in the good prognosis primary chemotherapy so as to identify factors predictive group (0 factor), high-dose therapy after response to of survival after ASCT and to validate previous factors described in relapsing HD. 7, 8, 11, 16 Correspondence: Dr P Brice, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux 75475 Paris Cedex 10, France Received 5 December 1996; accepted 12 March 1997 engraftment information, toxicity. Also recorded were: date of relapse, site of relapse expressed as nodal or extranodal (EN), response to second-line therapy, date of progression the 220 patients in first relapse, the interval between endafter ASCT, date and cause of death.
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of-treatment and relapse was Ͻ12 months for 34% and the median interval was 18 months. The majority of patients were in first relapse, 19% were in second and 3% in third Definitions relapse. The localization of the relapse, classified as nodal The interval between the end-of-treatment and relapse was (47%) or EN (53%) was available for 238 patients. All used to evaluate time to relapse. Patients were considered patients received a second-line regimen for HD relapse. to have chemosensitive relapses when an objective response Eighty-four percent of patients were subsequently defined (decrease Ͼ50% of all measurable volumes and absence of as chemosensitive and 180 were in second CR before high-B-symptoms) was observed after salvage chemotherapy for dose therapy. The interval between the date of relapse and relapse; the remaining patients were considered to have high-dose therapy ranged from 2 to 18 months with a refractory relapse even if they responded to another chemomedian of 5 months. After high-dose therapy and ASCT, therapeutic regimen.
36 patients (13%) received further radiotherapy.
Patient characteristics Stem cell collection
Bone marrow (BM) was harvested under general anesthesia The characteristics at diagnosis of the 280 patients included in this study are summarized in Table 1 . Male patients preand cryopreserved as previously described. 17 No ex vivo BM purging was used. Peripheral blood progenitor cells dominated in this population with a median age of 30 years; seven patients were children under 15 years old. Histologic (PBPC) were collected by leukaphereses during the phase of hematologic recovery after mobilizing chemotherapy as classification, available for 214 patients, consisted mostly of type 2 nodular sclerosis (64%) and type 3 mixed cellupreviously described. 18 More recently, leukaphereses were performed after 5-7 days of hematopoietic growth factor larity (28%); other types (lymphocyte predominance, lymphocyte depletion or unclassified) concerned only 8% of administration. When the progenitor cell population was insufficient, BM was harvested and all the stem cells colthe patients. Initial treatment varied according to the initial HD stage, the date of diagnosis and the protocol used in lected (BM and PB) were reinfused into patients.The minimum number of granulocyte-macrophage colony-forming each hospital; all patients received chemotherapy (MOPP or MOPP/ABV or ABVD) as initial treatment. The interval units or CD34-positive cells for autografting was defined in each center. between the date of diagnosis and the date of ASCT ranged from 12 to 186 months, with a median of 34 months. For
The reasons for using BM or PBPC have changed over 2 ) or high-dose cytaramost patients (n = 213), with peripheral stem cell support bine. After high-dose therapy, stored autologous stem cells increasing in recent years. Hematologic recovery was were thawed at the bedside and immediately infused intrawithin normal ranges; a median of 17 days to reach a neuvenously. All patients had indwelling central venous cathtrophil count Ͼ500/l and 24 days to reach a platelet count eters and were treated in a protected environment. For Ͼ50 000/l. Fifteen patients (6%) died from transplantfevers up to 38°C, patients received broad-spectrum antirelated toxicities: sepsis (n = 5), interstitial pneumopathy biotics after three blood sample cultures. Platelets or packed (n = 3), hemorrhage (n = 3), organ failure (n = 3), veno-RBC transfusions were given when necessary. All blood occlusive disease (n = 1). Four late deaths not attributable products were irradiated before infusion.
to HD were recorded, one patient died from viral infection 1 year after high-dose therapy and three patients in continuStatistical analysis ous CR died from second malignancies. The overall survival (OS) analysis took into account all deaths regardless of the cause. We defined transplantResponse to high-dose therapy related mortality as death with no evidence of disease durAfter high-dose therapy, 20 patients did not achieve CR ing the first 3 months. Because of the difficulty in assessing and 86 patients relapsed after entering remission or with CR in patients with HD and residual masses, progressionstable residual disease. The median time to relapse was 15 free survival (PFS) was used. Progression was defined as months after high-dose therapy and ASCT. Subsequently, the persistence of evolutive disease after high-dose therapy 74 of progressive patients died of HD and 32 patients are or evidence of disease progression after remission. The still alive with progressive disease being further treated. In probability of PFS was calculated from the date of ASCT summary, among 280 patients, 155 are alive in continuto the time of last follow-up without evidence of progressous CR. ive HD and all patients were evaluable. Survival rates were calculated from the date of ASCT to death or date of the last follow-up using the Kaplan and Meier method 19 and Univariate analysis for survival were compared using the log-rank test . Variables analyzed
The median follow-up period after ASCT was 36 months as prognostic indicators included the following: age, sex, (range 12-115 months) for all patients. The 4 year OS and initial stage, initial treatment, interval between the end-of-PFS were, respectively, 66 and 60% (Figure 1 ). The median treatment and relapse, site of relapse (nodal vs EN), contime from second progression was 56 months and the ditioning regimen, stem cell source, sensitivity to chemomedian survival has not yet been reached. Factors influenctherapy prior to high-dose therapy.
ing survival are shown in Table 3 . Prognosis was significantly better when relapses were chemosensitive (P Ͻ 0.001), the interval between end-of-treatment and relapse Results was у12 months (for patients in first relapse) (P = 0.05), when the relapse was nodal vs EN relapse (P Ͻ 0.001) and Patient outcome when it was the first, vs subsequent relapse (P Ͻ 0.05).
Results were the same for chemosensitive patients whether Transplant modalities are summarized in Table 2 . Briefly, the conditioning regimen was based on chemotherapy and or not they were in second CR. Age, sex, stage, initial treatment, stem cell source and conditioning regimen had no the majority of the patients received a BEAM regimen (n = 168). 9 The source of stem cells was the bone marrow in influence.
of patients with late relapse is too small and the number of events too rare to study other prognostic factors in this favourable subgroup.
Validation of the prognostic model
For 214 patients in first relapse, we analyzed two significant prognostic factors, the interval between the end-of-treatment and relapse and the site of relapse (nodal vs EN) in order to validate our previously published prognostic model. 16 Three subgroups were defined: 0 factor (n = 59), (P Ͻ 0.001) (Figure 2 ). 
Months
We analyzed patients having late relapses, eg more than 3 with an OS at 4 years of 81 vs 65% (P Ͻ 0.05). The group able at the time of relapse: duration of CR, stage at relapse, finding has not been established in all studies but may reflect the poor prognosis for patients receiving three or B-symptoms, performance status, EN disease or relapse within an irradiated field.
20 Their importance is difficult to more lines of treatment before intensive treatment. 10, 14 No influence of conditioning regimen or stem cell source was interpret because series are often heterogeneous and multivariate analyses have not been performed systematically. In found in this large series of patients. We were able to validate a prognostic model for patients a report on the outcome of treatment of first relapse after primary chemotherapy in 80 patients, Lohri et al 7 described in the first relapse of HD in 214 of such patients, using two factors: interval from end-of-treatment to relapse Ͻ12 three predominant adverse prognostic factors predicting for freedom from second failure (FF2F): stage IV disease at months and the presence of extranodal disease. With these factors we can classify patients in the first relapse of HD diagnosis, B-symptoms at relapse and an interval from primary treatment to relapse Ͻ1 year. Actuarial FF2F at 5 into three different subgroups with significantly different survival rates after high-dose therapy. years was 17% in the group of patients with one or more of these factors, and 82% in the group of patients with none
In conclusion, high-dose therapy should be used for all relapsed patients not cured by second-line radiotherapy or of these factors. The influence of type of salvage therapy, either intensive or conventional, did not determine outwho relapsed early. 7, 11, 16 For the patients without adverse prognostic factors, the role of high-dose therapy has not yet come. More recently, analysis of outcome after first relapse in a series of 58 patients treated with high-dose chemobeen clarified and when relapse occurs after a long interval in a non-irradiated site, combined modality salvage therapy therapy followed by ASCT at the same institution was reported. Four prognostic subgroups were identified accordleads to good results. High-dose therapy can be proposed only if a second relapse occurs. 22 These data must be evaluing to the presence of the following parameters at relapse: none, B-symptoms at relapse, EN disease, and initial ated in the context of the high mortality of long-term survivors after treatment for HD, not due to the disease remission duration of Ͻ1 year. 11 We recently analyzed 187 patients in first relapse of HD itself. 23, 24 Conversely, some patients with disseminated, or early relapses unresponsive to second-line chemotherapy after primary chemotherapy. Two prognostic factors were identified by multivariate analysis as determining outcome have a very poor outcome even with ASCT. For these patients, other therapeutic approaches including more intenafter relapse, both in terms of FF2F and OS: interval between the end-of-treatment and relapse (Ͻ vs у12 sive regimens, 25,26 two courses of high-dose therapy or immunomodulation post-ASCT are required. months) and stage at relapse (I-II vs III-IV). 16 The presence of B-symptoms, closely associated with the relapse stage, was not relevant in this model. Nevertheless, in this retrospective study there was a trend, although not signifiReferences cant, for a better outcome after intensive therapy, especially for patients with at least one adverse prognostic factor at
